Amphista Therapeutics will present new preclinical data at ASH 2025 for AMX-883, an oral targeted glue degrader of BRD9, showing survival benefit in murine models, reduced leukemic burden in patient-derived xenografts, and synergy with venetoclax, including prevention of venetoclax resistance in vitro. The company has nominated AMX-883 as its first clinical candidate in acute myeloid leukemia, secured additional Series B funding tied to that nomination, and is guiding to a first-in-human study in the second half of 2026. Beyond AML, Amphista disclosed progress across its Eclipsys platform, including a TEAD degrader that leverages FBXO22 and highly selective SMARCA2-directed degraders, and reported a discovery milestone under its collaboration with Merck KGaA.
The signal here is strategic as much as scientific: a karyotype-independent differentiation agent that potentiates venetoclax and may blunt the biology of resistance goes straight at the central weakness of today’s AML standard in older or unfit patients. If AMX-883 can convert transient venetoclax responses into deeper, more durable remissions without additive toxicity, Amphista could reposition itself from a platform story to a regimen enabler. The core question is whether the prevention-of-resistance narrative can be clinically substantiated early enough to shape trial design, partnership interest, and payer expectations.
This matters now because venetoclax-based doublets dominate frontline therapy in high-risk AML, yet resistance often emerges via upregulation of anti-apoptotic proteins such as MCL-1. A BRD9 degrader that drives myeloid differentiation and disrupts that adaptive escape could extend time on therapy and expand the addressable population regardless of genetic profile. For patients, the promise is longer disease control without complex genomic triage. For hematologists, an oral agent with clear pharmacodynamic markers of differentiation could be straightforward to integrate into existing venetoclax/azacitidine pathways, provided differentiation syndrome and myelosuppression are manageable. For payers, a triplet regimen that delays relapse and reduces inpatient utilization would have a defensible value case, but only if gains in response durability and survival are clinically meaningful and accompanied by a tight biomarker strategy to confirm on-target degradation.
For competitors, the move pushes targeted protein degradation deeper into hematology, where menin inhibitors and IDH inhibitors have reinvigorated the differentiation paradigm. A BRD9 approach that is karyotype-agnostic raises the bar for breadth of benefit. It also underscores a broader industry shift toward “TPD 2.0” modalities that escape CRBN/VHL limitations, a theme likely to animate dealmaking as ASH data flow into J.P. Morgan dialogues. Financing dynamics are equally telling: a Series B extension tied to candidate nomination illustrates how investors are rewarding platform-to-program conversion with clinically credible timelines, while leaving room for a risk-sharing partnership at or before dose-escalation.
Medical Affairs teams should prioritize translational design: robust assays for BRD9 degradation, time-dependent differentiation markers, and early MRD readouts will be essential to de-risk the mechanism. Safety monitoring frameworks for differentiation events and marrow recovery will shape clinician confidence. Commercial teams should map sequencing against menin inhibitors and plan for pragmatic evidence—duration of response and time to next treatment—that resonates with payers managing escalating oncology combination costs.
The next milestone is simple but unforgiving: can Amphista deliver clean on-target pharmacodynamics and early signs of resistance delay in the first AML cohorts quickly enough to catalyze a partner and define a registrational path, or will targeted glues remain a compelling platform waiting for a definitive hematology win?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
